These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 34793476)

  • 1. Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill-An interim analysis of a nationwide cohort study.
    Baum U; Poukka E; Palmu AA; Salo H; Lehtonen TO; Leino T
    PLoS One; 2021; 16(11):e0258704. PubMed ID: 34793476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron.
    Baum U; Poukka E; Leino T; Kilpi T; Nohynek H; Palmu AA
    BMC Infect Dis; 2022 Nov; 22(1):816. PubMed ID: 36335289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden.
    Nordström P; Ballin M; Nordström A
    PLoS Med; 2023 Feb; 20(2):e1004127. PubMed ID: 36802397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
    Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
    Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.
    Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B
    PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data.
    Glatman-Freedman A; Bromberg M; Dichtiar R; Hershkovitz Y; Keinan-Boker L
    EBioMedicine; 2021 Oct; 72():103574. PubMed ID: 34537449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study.
    Florea A; Sy LS; Luo Y; Qian L; Bruxvoort KJ; Ackerson BK; Lee GS; Ku JH; Tubert JE; Tian Y; Talarico CA; Tseng HF
    PLoS One; 2022; 17(4):e0267824. PubMed ID: 35482785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
    Embi PJ; Levy ME; Naleway AL; Patel P; Gaglani M; Natarajan K; Dascomb K; Ong TC; Klein NP; Liao IC; Grannis SJ; Han J; Stenehjem E; Dunne MM; Lewis N; Irving SA; Rao S; McEvoy C; Bozio CH; Murthy K; Dixon BE; Grisel N; Yang DH; Goddard K; Kharbanda AB; Reynolds S; Raiyani C; Fadel WF; Arndorfer J; Rowley EA; Fireman B; Ferdinands J; Valvi NR; Ball SW; Zerbo O; Griggs EP; Mitchell PK; Porter RM; Kiduko SA; Blanton L; Zhuang Y; Steffens A; Reese SE; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron MA; Thompson MG; DeSilva MB
    MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1553-1559. PubMed ID: 34735426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis.
    Meeraus W; de Munter L; Gray CM; Dwivedi A; Wyndham-Thomas C; Ouwens M; Hartig-Merkel W; Drikite L; Rebry G; Carmona A; Stuurman AL; Chi Nguyen TY; Mena G; Mira-Iglesias A; Icardi G; Otero-Romero S; Baumgartner S; Martin C; Taylor S; Bollaerts K
    Lancet Reg Health Eur; 2023 Aug; 31():100675. PubMed ID: 37547274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
    Gomes D; Beyerlein A; Katz K; Hoelscher G; Nennstiel U; Liebl B; Überla K; von Kries R
    PLoS One; 2021; 16(11):e0259370. PubMed ID: 34739520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study.
    Bruxvoort KJ; Sy LS; Qian L; Ackerson BK; Luo Y; Lee GS; Tian Y; Florea A; Takhar HS; Tubert JE; Talarico CA; Tseng HF
    Lancet Reg Health Am; 2022 Feb; 6():100134. PubMed ID: 34849505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers' unvaccinated household members.
    Salo J; Hägg M; Kortelainen M; Leino T; Saxell T; Siikanen M; Sääksvuori L
    Nat Commun; 2022 Mar; 13(1):1162. PubMed ID: 35246536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection: A Preliminary Report.
    Bianchi FP; Germinario CA; Migliore G; Vimercati L; Martinelli A; Lobifaro A; Tafuri S; Stefanizzi P;
    J Infect Dis; 2021 Aug; 224(3):431-434. PubMed ID: 34007998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021.
    Pilishvili T; Fleming-Dutra KE; Farrar JL; Gierke R; Mohr NM; Talan DA; Krishnadasan A; Harland KK; Smithline HA; Hou PC; Lee LC; Lim SC; Moran GJ; Krebs E; Steele M; Beiser DG; Faine B; Haran JP; Nandi U; Schrading WA; Chinnock B; Henning DJ; LoVecchio F; Nadle J; Barter D; Brackney M; Britton A; Marceaux-Galli K; Lim S; Phipps EC; Dumyati G; Pierce R; Markus TM; Anderson DJ; Debes AK; Lin M; Mayer J; Babcock HM; Safdar N; Fischer M; Singleton R; Chea N; Magill SS; Verani J; Schrag S;
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):753-758. PubMed ID: 34014909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
    Antunes L; Mazagatos C; Martínez-Baz I; Naesens R; Borg ML; Petrović G; Fatukasi T; Jancoriene L; Machado A; Oroszi B; Husa P; Lazar M; Dürrwald R; Howard J; Melo A; Pérez-Gimeno G; Castilla J; Bernaert E; Džiugytė A; Makarić ZL; Fitzgerald M; Mickienė A; Gomez V; Túri G; Součková L; Marin A; Tolksdorf K; Nicolay N; Rose AMC;
    Influenza Other Respir Viruses; 2024 Aug; 18(8):e13360. PubMed ID: 39145535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.
    Kislaya I; Sentís A; Starrfelt J; Nunes B; Martínez-Baz I; Nielsen KF; AlKerwi A; Braeye T; Fontán-Vela M; Bacci S; Meijerink H; Castilla J; Emborg HD; Hansen CH; Schmitz S; Van Evercooren I; Valenciano M; Nardone A; Nicolay N; Monge S;
    Influenza Other Respir Viruses; 2023 Nov; 17(11):e13195. PubMed ID: 38019704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.